Rexahn has a robust pre-clinical oncology product pipeline that features potential novel therapeutics:
RX-21101: Nano-polymer Anticancer Drug
RX-21101 is a nano-polymer anticancer drug that combines its nano-drug delivery system with docetaxel, a widely used FDA approved chemo drug. RX-21101 may bolster efficacy while lowering toxicity of FDA approved chemo drugs by specific tumor targeting and increased stability in the body. Potential indications include breast, ovarian, prostate and lung cancer.
Archexin-Nano: Nanoliposomal anticancer Akt1 inhibitor
RX-0201, the active ingredient of Archexin®, is a first-in-class, potent inhibitor of the Akt1 protein kinase. RX-0201-Nano is a nano-liposomal product of RX-0201, the active ingredient in Archexin. Nano-liposomal delivery of RX-0201 may provide significant clinical benefits including reduced drug-related toxicity and improved efficacy. Potential indications include solid tumors and hematological malignancies, which are cancers that the affect blood, bone marrow, and lymph nodes.